Hiromitsu Kumada

机构：Toranomon Hospital

发表论文 707 篇 · 总被引 30667 次 · h-index 83

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 455)
• Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma (2023 · Cancers · 被引 13)
• HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative (2023 · JHEP Reports · 被引 12)
• Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients (2025 · Hepatology · 被引 11)
• Newly established borderline resectable 1 (BR1) category is one of the favorable candidates for selecting the use of multidisciplinary combination therapy in patients with advanced hepatocellular carcinoma treated with systemic therapy (2024 · Hepatology Research · 被引 9)
• LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma. (2025 · Journal of Clinical Oncology · 被引 7)